Jul 30, 2026 05:59AM
Jul 27, 2026 12:31PM
Mar 10, 2026 10:05AM
Dec 5, 2025 06:15AM
Dec 5, 2025 06:15AM
Dec 3, 2025 01:38PM
Sep 12, 2025 06:46AM H.C. Wainwright Reiterates Buy Rating on Capricor Therapeutics (CAPR)
Aug 19, 2025 06:40AM
Jul 14, 2025 06:58AM
Jun 24, 2025 12:29PM
Jun 23, 2025 06:43AM
Jun 16, 2025 06:39AM
Jun 13, 2025 11:28AM
May 13, 2025 04:05PM Capricor Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Mar 18, 2025 06:42AM
Mar 5, 2025 06:48AM
Jan 3, 2025 06:36AM
Oct 10, 2024 06:56AM
Sep 25, 2024 06:38AM
Sep 18, 2024 06:43AM
Sep 6, 2024 08:30AM Capricor Therapeutics to Present at Upcoming Investor and Scientific Conferences
Aug 7, 2024 04:05PM
Jul 2, 2024 06:40AM
May 13, 2024 04:05PM
Mar 21, 2024 08:30AM
Oct 4, 2023 06:23AM
Sep 29, 2023 07:36AM
Sep 29, 2023 07:35AM Capricor Therapeutics Announces $23 Million Registered Direct Offering
Sep 7, 2022 08:00AM
Aug 10, 2022 04:05PM
May 18, 2022 09:00AM
Jan 31, 2022 06:07AM
Oct 11, 2021 07:07AM
Sep 7, 2021 09:00AM
Sep 10, 2020 09:15AM Capricor Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment Conference
Dec 19, 2019 01:14PM
Dec 17, 2019 01:54PM
Dec 17, 2019 01:52PM
Sep 6, 2019 07:30AM
Jul 15, 2019 11:57AM
Dec 31, 2018 07:15AM
Jan 26, 2018 07:45AM UPDATE: Capricor Therapeutics (CAPR): Pivotal Year With HOPE-2 Start and Execution; PT to $8.60 - HC Wainwright
Sep 15, 2017 09:39AM
Jul 6, 2016 08:11AM

21,798 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All